Optionele productanalyse
Met uw toestemming gebruiken we privacyvriendelijke, beperkte analyses om te begrijpen welke onderzoeksroutes werken. We gebruiken geen advertentietrackers of sessieopnamen. U kunt deze keuze wijzigen in Voorkeuren. Lees het Privacybeleid.
Platform modernization concluding ahead of schedule, allowing capex to normalize toward maintenance levels and expanding free cash flow toward Potential value of $226.92.
Policy issuance and renewal revenue declining below $3,000M within a rolling 12-month period.
We assign a Sell rating to Erie Indemnity Company. The report-date price of $239.05 as of 2026-09-18 stands 36.7% above Fair value of $151.31 and exceeds Potential value of $226.92. Downside risk is concentrated in policy issuance fees dropping below $3,000M. Outperformance requires accelerated regional policy expansion and capex normalization.467
The Sell rating indicates that shares carry substantial downside risk and lack a margin of safety. Ordinary investors should exit or trim existing holdings rather than allocating new capital.
At $239.05 on 2026-09-18, shares trade at 26.74x forward earnings, far above our Fair value of $151.31 and Potential value of $226.92.4
The primary risk is policy fee revenue of $3,131.81M in FY2025 slowing below $3,000M if underwriting losses or rate approval delays strike the Exchange.7
Upside requires regional policy expansion and technology capex easing from $115.69M in FY2025 toward maintenance levels, lifting free cash flow toward Potential value of $226.92.56
Exclusive perpetual attorney-in-fact agreement with Erie Insurance Exchange secures management fee revenues without underwriting exposure.7
Deep operational integration and administrative governance make replacing the management entity legally and operationally prohibitive.6
Accelerating premium rate approvals and policy count gains drive regional premium expansion, lifting management fee receipts without requiring balance-sheet capital.
Sell: the share price of $239.05 trades at a steep premium above Fair value of $151.31, offering no margin of safety against mature top-line fee growth.4
Its employees also share in its values to give back and make a positive difference in their communities. ERIE INDEMNITY COMPANY offers a volunteer program that provides employees with an allotment of paid hours annually to volunteer with eligible nonprofit organizations. Market competition bears directly on the price charged for insurance products and services subject to regulatory limitations. Industry capital levels can also significantly affect prices charged for coverage. Growth is driven by a company's ability to provide insurance services and competitive prices while maintaining target profitability.
Technological development is necessary to facilitate ease of doing business for employees, agents, and customers. As the company continues to develop technology initiatives in order to remain competitive, its profitability could be negatively impacted as the company invests in system development.
Under stressed operating conditions where premium growth stalls and terminal multiples converge with peer medians near 12.8x, annual free cash flow contracts and fair value declines toward the low range of $106.25.
In the downside scenario, catastrophic weather losses deplete exchange surplus and state regulators delay rate filings, constraining premium volume. Meanwhile, elevated software expenditures persist and valuation multiples contract toward insurance industry averages.
Policy issuance and renewal revenue of $3,131.81M in FY2025 drops below $3,000M due to underwriting stress or rate pushback at the Exchange, triggering multi-year earnings contraction.7
De vijf ontwikkelingen die onze beleggingsthese zouden verzwakken.
A decline in policy issuance fees indicates direct written premium contraction or commission concessions at the Exchange, impairing the primary cash-generating engine and reducing earnings available to distribute to shareholders.
Huidig:$3,131.81M in FY2025
Waarschuwing alsDeclines below $3,000M within any rolling 12-month period
Erie Indemnity possesses a narrow competitive moat anchored in its exclusive, perpetual role as attorney-in-fact for Erie Insurance Exchange. Contractual management fees from policy issuance and renewal generated $3,131.81M in FY2025, representing 77.0% of total revenue. This asset-light structure insulates the company from property and casualty underwriting losses while earning high returns on equity.
Moat durability remains stable because the century-old partnership aligns shareholder returns with Exchange policy growth. However, the moat does not provide pricing power independent of state insurance department rate approvals.
Sustained return on equity of 24.81% exceeds the estimated cost of equity of 7.03%.26
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Apply a terminal P/E to the dated forward path, then discount that future share value back to the analysis date.
None of the valuation methods used to calculate Fair value relies on a separate assumption about how long the competitive advantage lasts.
The highlighted cell is Fair value when every assumption sits at its base level ($151.31). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $536.3M after modeled reinvestment of $31.0M, with terminal value at 51.1% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to revenue, reinvestment, or gross margin resets materially.
In the base scenario, management fee revenue grows steadily in line with regional premium expansion while operating margins remain stable. Reinvestment moderates gradually, aligning intrinsic worth with Fair value $151.31 against the share price at analysis $239.05.
Accelerating premium revenue and margin expansion narrow the valuation gap to intrinsic worth
Steady fee collection maintains cash generation, yet the share price at analysis $239.05 remains far above Fair value $151.31
Top-line deceleration narrows cash conversion and reinforces that the stock trades above Fair value $151.31
Earnings quality is supported by high cash conversion where operating cash flow comfortably exceeds reported net income, with no inventory risk, negligible customer credit exposure, and absence of balance-sheet debt distress.
Fee revenue from policy issuance drives the vast majority of operating income and determines overall cash generation
Operating cash flow reached $686.66M in FY2025, converting 122.8% of net income of $559.34M. Free cash flow expanded to $570.97M as capital spending receded from $124.85M in FY2024 to $115.69M in FY2025.56
Capital allocation prioritizes shareholder distributions and platform modernization. The balance sheet carries minimal total debt of $63.16M, while dividends paid of $254.28M in FY2025 represented a conservative 44.5% payout of free cash flow, leaving ample liquidity for technology investments.
High excess economic returns persist because the management contract requires minimal physical invested capital, generating sustained residual income.
Return on equity of 24.81% substantially exceeds the 7.01% cost of capital.
Capex decreased from $124.85M in FY2024 to $115.69M in FY2025.
Normalization toward maintenance capex of $54.0M will release incremental annual free cash flow.
Operating cash flow of $686.66M exceeded of $559.34M in FY2025.
| Omzet | US$ 3.795.115.000 |
|---|---|
| Kostprijs van de omzet | US$ 3.118.660.000 |
| Brutowinst | US$ 676.455.000 |
| Bedrijfskosten | US$ 0 |
| Bedrijfsresultaat | US$ 676.455.000 |
| Niet-operationele posten en belastingen | US$ -76.141.000 |
| Nettowinst | US$ 600.314.000 |
| Totale activa | US$ 3.355.481.000 |
|---|---|
| Liquide middelen | US$ 345.874.000 |
| Vlottende activa | US$ 1.199.173.000 |
| Totale verplichtingen | US$ 1.072.107.000 |
| Kortlopende verplichtingen | US$ 945.587.000 |
| Eigen vermogen | US$ 2.283.374.000 |
| Nettowinst | US$ 559.335.000 |
|---|---|
| Operationele instroom | US$ 723.579.000 |
| Afschrijvingen en amortisatie | US$ 69.450.000 |
| Aandelenbeloning | US$ 94.794.000 |
| Operationele kasstroom | US$ 686.657.000 |
| Operationele uitstroom | US$ 36.922.000 |
| Beschikbare liquide middelen | US$ 985.054.000 |
| Beginstand liquide middelen | US$ 298.397.000 |
| Investeringsuitstroom | US$ 439.328.000 |
| Investeringen | US$ 115.692.000 |
| Overige investeringsactiviteiten | US$ 323.636.000 |
| Financieringsuitstroom | US$ 199.852.000 |
| Eindstand liquide middelen | US$ 345.874.000 |
| Investeringskasstroom | US$ -439.328.000 |
| Financieringskasstroom | US$ -199.852.000 |
Bron: SEC EDGAR · Ingediend 2026-02-23 · SEC EDGAR
| Omzet per bedrijfscategorie | Omzet | Aandeel | j-o-j |
|---|---|---|---|
| Policy Issuanceand Renewal Services | US$ 3,1 mld. | 77% | 8,2% |
| Administrative Services Reimbursements | US$ 836,6 mln. | 20,6% | 3,8% |
| Administrative Services Management Fee | US$ 74,1 mln. | 1,8% | 8,3% |
| Service Agreement | US$ 24,8 mln. | 0,6% | -6,1% |
Financiële momentopname gebruikt in de analyse van 2026-09-20.
| Periode | Omzet | EBITDA | Nettowinst | Operationele kasstroom | Vrije kasstroom | Investeringen | Afschrijvingen en amortisatie | Aandelenbeloning | Aandeleninkoop | Betaalde dividenden | Netto schuldemissie | Investeringskasstroom | Financieringskasstroom | Beginstand liquide middelen | Eindstand liquide middelen | Kas en beleggingen | Totale schuld | Operationele marge | ROIC | WACC | ROIC−WACC-spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | US$ 1,6 mld. | US$ 320,2 mln. | US$ 210,4 mln. | US$ 254,3 mln. | US$ 229,1 mln. | US$ 25,2 mln. | US$ 15,1 mln. | US$ 9,5 mln. | US$ 0 | US$ 136 mln. | — | -US$ 136,9 mln. | -US$ 111,2 mln. | — | US$ 189,1 mln. | US$ 245,2 mln. | US$ 235,3 mln. | 18,4% | — | 4,9% | — |
| 2017-12-31 | US$ 1,7 mld. | US$ 316,9 mln. | US$ 197 mln. | US$ 197,1 mln. | US$ 168,2 mln. | US$ 28,9 mln. | US$ 14,8 mln. | US$ 12,8 mln. | — | US$ 145,8 mln. | — | -US$ 74,7 mln. | -US$ 95,8 mln. | US$ 189,1 mln. | US$ 215,7 mln. | US$ 286,9 mln. | US$ 302,9 mln. | 17,2% | — | 5,0% | — |
| 2018-12-31 | US$ 2,4 mld. | US$ 373,8 mln. | US$ 288,2 mln. | US$ 263,6 mln. | US$ 207,3 mln. | US$ 56,3 mln. | US$ 13,4 mln. | US$ 7,5 mln. | — | US$ 156,5 mln. | — | -US$ 81,4 mln. | -US$ 131,5 mln. | US$ 215,7 mln. | US$ 266,4 mln. | US$ 668,8 mln. | US$ 99,7 mln. | 14,5% | — | 5,1% | — |
| 2019-12-31 | US$ 2,5 mld. | -US$ 212,9 mln. | US$ 316,8 mln. | US$ 364,5 mln. | US$ 262,5 mln. | US$ 102 mln. | US$ 16,8 mln. | US$ 8,9 mln. | — | US$ 167,7 mln. | — | -US$ 124,6 mln. | -US$ 169,6 mln. | US$ 266,4 mln. | US$ 336,7 mln. | US$ 371,9 mln. | US$ 119,8 mln. | 14,4% | — | 4,8% | — |
| 2020-12-31 | US$ 2,5 mld. | -US$ 266,7 mln. | US$ 293,3 mln. | US$ 342,6 mln. | US$ 287,1 mln. | US$ 55,5 mln. | US$ 21,2 mln. | US$ 13,6 mln. | — | US$ 272,9 mln. | — | -US$ 243,2 mln. | -US$ 274,9 mln. | US$ 336,7 mln. | US$ 161,2 mln. | US$ 178,9 mln. | US$ 95,9 mln. | 13,3% | — | 2,6% | — |
| 2021-12-31 | US$ 2,6 mld. | -US$ 286,1 mln. | US$ 297,9 mln. | US$ 402,8 mln. | US$ 254 mln. | US$ 148,8 mln. | US$ 37,2 mln. | US$ 4 mln. | — | US$ 192,8 mln. | -US$ 2 mln. | -US$ 185,5 mln. | -US$ 194,8 mln. | US$ 161,2 mln. | US$ 183,7 mln. | US$ 222,1 mln. | US$ 93,8 mln. | 12,1% | — | 3,2% | — |
| 2022-12-31 | US$ 2,8 mld. | US$ 428,4 mln. | US$ 298,6 mln. | US$ 366,2 mln. | US$ 298,9 mln. | US$ 67,2 mln. | US$ 45,9 mln. | -US$ 1,5 mln. | — | US$ 206,8 mln. | -US$ 94,1 mln. | -US$ 106,9 mln. | -US$ 300,8 mln. | US$ 183,7 mln. | US$ 142,1 mln. | US$ 166,4 mln. | US$ 122,5 mln. | 13,2% | — | 5,6% | — |
| 2023-12-31 | US$ 3,3 mld. | US$ 600,2 mln. | US$ 446,1 mln. | US$ 381,2 mln. | US$ 288,6 mln. | US$ 92,6 mln. | US$ 47,4 mln. | US$ 12,2 mln. | — | US$ 221,7 mln. | US$ 0 | -US$ 157,6 mln. | -US$ 221,7 mln. | US$ 142,1 mln. | US$ 144,1 mln. | US$ 226,1 mln. | US$ 112,3 mln. | 15,9% | — | 5,6% | — |
| 2024-12-31 | US$ 3,8 mld. | US$ 766,3 mln. | US$ 600,3 mln. | US$ 611,2 mln. | US$ 486,4 mln. | US$ 124,8 mln. | US$ 56,5 mln. | -US$ 94,9 mln. | — | US$ 237,5 mln. | US$ 0 | -US$ 226,9 mln. | -US$ 230 mln. | US$ 144,1 mln. | US$ 298,4 mln. | US$ 343 mln. | US$ 7,5 mln. | 17,8% | — | 6,0% | — |
| 2025-12-31 | US$ 4,1 mld. | US$ 787,4 mln. | US$ 559,3 mln. | US$ 686,7 mln. | US$ 571 mln. | US$ 115,7 mln. | US$ 69,5 mln. | -US$ 94,8 mln. | — | US$ 254,3 mln. | — | -US$ 439,3 mln. | -US$ 199,9 mln. | US$ 298,4 mln. | US$ 345,9 mln. | US$ 383,2 mln. | — | 17,6% | — | — | — |
Erie Indemnity Company (ERIE) trades at 26.7x forward earnings against a peer median of 12.8x. Its EV/EBITDA of 14.7x compares with a peer median of 9.9x. The comparison uses 4 peers: Arthur J. Gallagher & Co., Globe Life Inc., Assurant Inc. and Brown & Brown Inc., as of 2026-09-20.
Capex crested at $124.85M in FY2024 and eased to $115.69M in FY2025, above industry capex-to-revenue benchmarks.6
Accelerating premium rate approvals and policy count gains drive regional premium expansion, lifting management fee receipts without requiring balance-sheet capital.
Severe catastrophe losses deplete Exchange surplus, while state regulators delay rate filings, constraining premium volume growth to 0.5%.
ERIE maintains peer-leading operating margins of 17.63% compared to Assurant at 11.73%, defending regional market share through dedicated agent relationships despite slower top-line expansion than national peers.36
A zero allocation is warranted under our Sell rating because the shares trade at a substantial premium of 36.7% above house Fair value of $151.31, leaving no margin of safety.
Risk management requires strict capital preservation. With shares trading at 26.74x forward earnings versus a 13.0x terminal multiple, investors face severe capital loss if valuation multiples compress toward peers.
Trading at 26.74x forward P/E against peer median of 12.76x, shares lack any margin of safety relative to Fair value of $151.31.4
Despite a reliable $5.85 dividend per share, severe capital depreciation risk outweighs cash yield benefits at the report-date price of $239.05.4
Projected top-line growth of 0.5% in FY2026 significantly lags broker peers expanding at over 30%.1
Sell shares of Erie Indemnity Company as the report-date price of $239.05 trades 36.7% above Fair value of $151.31.4
The premium valuation leaves investors exposed to severe multiple contraction without compensation from near-term revenue growth.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
The records this analysis drew on, as they stood when it was run.
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
Forward price-to-earnings multiple of 26.74x compresses toward peer median multiple of 12.76x, driving sharp equity de-rating.4
Cost of equity increases 200 basis points above 7.03% amid elevated risk-free yields, depressing capitalized equity valuations.2
Sustained capital expenditure above depreciation signals persistent software platform costs rather than a temporary modernization buildout, depressing free cash flow generation and restricting future dividend expansion.
Huidig:1.51x in FY2025
Waarschuwing alsRemains above 1.50x past FY2027
Multiple contraction toward insurance peer medians reflects market recognition of decelerating revenue growth, eroding the equity valuation premium despite stable administrative margin generation.
Huidig:26.74x as of 2026-09-20
Waarschuwing alsCompresses below 15.0x within 18 months
Negative top-line growth reveals policy attrition across core regional states and an inability to offset loss-cost inflation with approved premium rate filings, shrinking aggregate management fee receipts.
Huidig:0.5% in FY2026
Waarschuwing alsTurns negative across two consecutive reporting quarters
Earnings per share falling below historical run rates indicates operating expense inflation outstripping management fee income, undermining the earnings baseline required to support current shareholder payouts.
Huidig:$12.70 in FY2026
Waarschuwing alsDrops below $11.50 in FY2026 or FY2027
Use book value per share with normalized ROE, cost of equity, and terminal growth to derive a justified price-to-book value.
Discount the explicit dividend path and its Gordon-growth terminal value at cost of equity.
Limitation: Terminal value is 79.8% of this model's value, above the 60% level at which the methodology flags concentration; the value leans on the years beyond the explicit forecast.
Solve for the growth rate that makes the model value equal the report-date share price.
Moderating capital expenditures release operating cash flow to support shareholder dividends
Stable fee margins demonstrate cost reimbursement discipline under the management agreement
Policyholder retention protects the fee base against competitive encroachment from national brokerage consolidators
Sustained exchange surplus provides the underwriting capacity required to expand direct written premiums
| 2035 |
|---|
| Revenue | $4.09B | $4.19B | $4.29B | $4.40B | $4.51B | $4.62B | $4.74B | $4.86B | $4.98B | $5.10B |
| Revenue growth | 0.5% | 2.5% | 2.5% | 2.5% | 2.5% | 2.5% | 2.5% | 2.5% | 2.5% | 2.5% |
| Operating margin | 17.6% | 17.6% | 17.6% | 17.6% | 17.6% | 17.6% | 17.6% | 17.6% | 17.6% | 17.6% |
| Operating income | $720.75M | $738.74M | $757.18M | $776.08M | $795.45M | $815.34M | $835.72M | $856.62M | $878.03M | $899.98M |
| Tax rate | 21.3% | 21.3% | 21.3% | 21.3% | 21.3% | 21.3% | 21.3% | 21.3% | 21.3% | 21.3% |
| NOPAT | $567.30M | $581.46M | $595.97M | $610.85M | $626.10M | $641.76M | $657.80M | $674.24M | $691.10M | $708.38M |
| Reinvestment | $30.98M | $15.88M | $0.00 | $4.56M | $9.34M | $14.37M | $19.63M | $25.16M | $30.94M | $37.00M |
| Reinvestment rate (of NOPAT) | 5.5% | 2.7% | 0.0% | 0.8% | 1.5% | 2.2% | 3.0% | 3.7% | 4.5% | 5.2% |
| Depreciation and amortization | $69.80M | $71.54M | $73.33M | $75.16M | $77.04M | $78.97M | $80.94M | $82.97M | $85.04M | $87.17M |
| Free cash flow to firm | $536.32M | $565.58M | $595.97M | $606.29M | $616.76M | $627.39M | $638.17M | $649.09M | $660.16M | $671.38M |
| Terminal growth | 2.5% | 2.5% | 2.5% | 2.5% | 2.5% | 2.5% | 2.5% | 2.5% | 2.5% | 2.5% |
| Marge |
|---|
| ERIE | Erie Indemnity Company | $12.5B | 26.7x | 3.0x | 14.7x | 24.8% | — |
| AJG | Arthur J. Gallagher & Co. | $61.4B | 16.1x | 4.1x | 17.3x | 6.7% | 19.2% |
| GL | Globe Life Inc. | $13.3B | 10.5x | 2.2x | 9.7x | 20.9% | 24.6% |
| AIZ | Assurant Inc. | $13.9B | 12.0x | 1.0x | 8.1x | 18.3% | 11.7% |
| BRO | Brown & Brown Inc. | $21.8B | 13.5x | 3.3x | 10.0x | 10.0% | 41.8% |
